 Amyloid beta-Peptides
"Amyloid beta-Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue.
| Descriptor ID |
D016229
|
| MeSH Number(s) |
D12.644.024 D12.776.049.407.249.500 D12.776.543.039.500
|
| Concept/Terms |
Amyloid beta-Peptides- Amyloid beta-Peptides
- Amyloid beta Peptides
- beta-Peptides, Amyloid
- Alzheimer's ABP
- ABP, Alzheimer's
- Alzheimer ABP
- Alzheimers ABP
- Alzheimer's Amyloid Fibril Protein
- Amyloid AD-AP
- AD-AP, Amyloid
- Amyloid AD AP
- beta-Amyloid Protein
- Protein, beta-Amyloid
- beta Amyloid Protein
- Amyloid beta-Protein
- Amyloid beta Protein
- beta-Protein, Amyloid
- Amyloid beta-Proteins
- Amyloid beta Proteins
- beta-Proteins, Amyloid
- Amyloid Fibril Protein, Alzheimer's
- Amyloid Protein A4
- Protein A4, Amyloid
- Alzheimer beta-Protein
- Alzheimer beta Protein
- beta-Protein, Alzheimer
- Amyloid beta-Peptide
- Amyloid beta Peptide
- beta-Peptide, Amyloid
|
Below are MeSH descriptors whose meaning is more general than "Amyloid beta-Peptides".
Below are MeSH descriptors whose meaning is more specific than "Amyloid beta-Peptides".
This graph shows the total number of publications written about "Amyloid beta-Peptides" by people in UAMS Profiles by year, and whether "Amyloid beta-Peptides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 2 | 2 | | 2021 | 0 | 1 | 1 | | 2020 | 4 | 1 | 5 | | 2019 | 2 | 2 | 4 | | 2018 | 2 | 2 | 4 | | 2017 | 2 | 0 | 2 | | 2016 | 1 | 0 | 1 | | 2015 | 2 | 2 | 4 | | 2014 | 1 | 3 | 4 | | 2012 | 0 | 2 | 2 | | 2011 | 0 | 1 | 1 | | 2010 | 2 | 1 | 3 | | 2009 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2006 | 1 | 0 | 1 | | 2005 | 2 | 1 | 3 | | 2004 | 1 | 2 | 3 | | 2003 | 3 | 0 | 3 | | 2002 | 3 | 2 | 5 | | 2001 | 2 | 0 | 2 | | 2000 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1996 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Amyloid beta-Peptides" by people in Profiles over the past ten years.
-
Charidimou A, Boulouis G, Frosch MP, Baron JC, Pasi M, Albucher JF, Banerjee G, Barbato C, Bonneville F, Brandner S, Calviere L, Caparros F, Casolla B, Cordonnier C, Delisle MB, Deramecourt V, Dichgans M, Gokcal E, Herms J, Hernandez-Guillamon M, Jäger HR, Jaunmuktane Z, Linn J, Martinez-Ramirez S, Martínez-Sáez E, Mawrin C, Montaner J, Moulin S, Olivot JM, Piazza F, Puy L, Raposo N, Rodrigues MA, Roeber S, Romero JR, Samarasekera N, Schneider JA, Schreiber S, Schreiber F, Schwall C, Smith C, Szalardy L, Varlet P, Viguier A, Wardlaw JM, Warren A, Wollenweber FA, Zedde M, van Buchem MA, Gurol ME, Viswanathan A, Al-Shahi Salman R, Smith EE, Werring DJ, Greenberg SM. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022 08; 21(8):714-725.
-
Hindle A, Singh SP, Pradeepkiran JA, Bose C, Vijayan M, Kshirsagar S, Sawant NA, Reddy PH. Rlip76: An Unexplored Player in Neurodegeneration and Alzheimer's Disease? Int J Mol Sci. 2022 May 29; 23(11).
-
Bowroju SK, Penthala NR, Lakkaniga NR, Balasubramaniam M, Ayyadevara S, Shmookler Reis RJ, Crooks PA. Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease. Bioorg Med Chem. 2021 09 01; 45:116311.
-
Dungan CM, Valentino T, Vechetti IJ, Zdunek CJ, Murphy MP, Lin AL, McCarthy JJ, Peterson CA. Exercise-mediated alteration of hippocampal Dicer mRNA and miRNAs is associated with lower BACE1 gene expression and Aß1-42 in female 3xTg-AD mice. J Neurophysiol. 2020 12 01; 124(6):1571-1577.
-
Hendrix RD, Ou Y, Davis JE, Odle AK, Groves TR, Allen AR, Childs GV, Barger SW. Alzheimer amyloid-ß- peptide disrupts membrane localization of glucose transporter 1 in astrocytes: implications for glucose levels in brain and blood. Neurobiol Aging. 2021 01; 97:73-88.
-
Bowroju SK, Mainali N, Ayyadevara S, Penthala NR, Krishnamachari S, Kakraba S, Reis RJS, Crooks PA. Design and Synthesis of Novel Hybrid 8-Hydroxy Quinoline-Indole Derivatives as Inhibitors of Aß Self-Aggregation and Metal Chelation-Induced Aß Aggregation. Molecules. 2020 Aug 08; 25(16).
-
Bernath MM, Bhattacharyya S, Nho K, Barupal DK, Fiehn O, Baillie R, Risacher SL, Arnold M, Jacobson T, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, Kaddurah-Daouk R, Saykin AJ. Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers. Neurology. 2020 05 19; 94(20):e2088-e2098.
-
Ahmad RHMA, Fakhoury M, Lawand N. Electromagnetic Field in Alzheimer's Disease: A Literature Review of Recent Preclinical and Clinical Studies. Curr Alzheimer Res. 2020; 17(11):1001-1012.
-
Cuevas E, Rosas-Hernandez H, Burks SM, Ramirez-Lee MA, Guzman A, Imam SZ, Ali SF, Sarkar S. Amyloid Beta 25-35 induces blood-brain barrier disruption in vitro. Metab Brain Dis. 2019 10; 34(5):1365-1374.
-
Fertan E, Wong AA, Vienneau NA, Brown RE. Age and sex differences in motivation and spatial working memory in 3xTg-AD mice in the Hebb-Williams maze. Behav Brain Res. 2019 09 16; 370:111937.
-
Fertan E, Rodrigues GJ, Wheeler RV, Goguen D, Wong AA, James H, Stadnyk A, Brown RE, Weaver ICG. Cognitive Decline, Cerebral-Spleen Tryptophan Metabolism, Oxidative Stress, Cytokine Production, and Regulation of the Txnip Gene in a Triple Transgenic Mouse Model of Alzheimer Disease. Am J Pathol. 2019 07; 189(7):1435-1450.
-
Shahid M, Kim J, Leaver K, Hendershott T, Zhu D, Cholerton B, Henderson VW, Tian L, Poston KL. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE e4 allele. Neurobiol Dis. 2019 07; 127:278-286.
-
Hu L, Zhang R, Yuan Q, Gao Y, Yang MQ, Zhang C, Huang J, Sun Y, Yang W, Yang JY, Min ZL, Cheng J, Deng Y, Hu X. The emerging role of microRNA-4487/6845-3p in Alzheimer's disease pathologies is induced by Aß25-35 triggered in SH-SY5Y cell. BMC Syst Biol. 2018 12 14; 12(Suppl 7):119.
-
Ayyadevara S, Ganne A, Hendrix RD, Balasubramaniam M, Shmookler Reis RJ, Barger SW. Functional assessments through novel proteomics approaches: Application to insulin/IGF signaling in neurodegenerative disease'. J Neurosci Methods. 2019 05 01; 319:40-46.
-
Garvock-de Montbrun T, Fertan E, Stover K, Brown RE. Motor deficits in 16-month-old male and female 3xTg-AD mice. Behav Brain Res. 2019 01 01; 356:305-313.
-
Ahmed HA, Ishrat T, Pillai B, Fouda AY, Sayed MA, Eldahshan W, Waller JL, Ergul A, Fagan SC. RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial. J Neuroinflammation. 2018 Aug 13; 15(1):229.
-
Zhang YP, Brown RE, Zhang PC, Zhao YT, Ju XH, Song C. DHA, EPA and their combination at various ratios differently modulated Aß25-35-induced neurotoxicity in SH-SY5Y cells. Prostaglandins Leukot Essent Fatty Acids. 2018 09; 136:85-94.
-
Zhang Y, Jiao G, Song C, Gu S, Brown RE, Zhang J, Zhang P, Gagnon J, Locke S, Stefanova R, Pelletier C, Zhang Y, Lu H. An Extract from Shrimp Processing By-Products Protects SH-SY5Y Cells from Neurotoxicity Induced by Aß25-35. Mar Drugs. 2017 Mar 22; 15(3).
-
Wang W, Bodles-Brakhop AM, Barger SW. A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid ß -Peptide from the Brain. Curr Alzheimer Res. 2016; 13(6):615-20.
-
Saunders JC, Young LM, Mahood RA, Jackson MP, Revill CH, Foster RJ, Smith DA, Ashcroft AE, Brockwell DJ, Radford SE. An in vivo platform for identifying inhibitors of protein aggregation. Nat Chem Biol. 2016 Feb; 12(2):94-101.
-
Howell MD, Bailey LA, Cozart MA, Gannon BM, Gottschall PE. Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APPswe/PS1dE9 mice. Acta Neuropathol Commun. 2015 Sep 04; 3:54.
-
Sooy K, Noble J, McBride A, Binnie M, Yau JL, Seckl JR, Walker BR, Webster SP. Cognitive and Disease-Modifying Effects of 11ß-Hydroxysteroid Dehydrogenase Type 1 Inhibition in Male Tg2576 Mice, a Model of Alzheimer's Disease. Endocrinology. 2015 Dec; 156(12):4592-603.
-
Bharate JB, Batarseh YS, Wani A, Sharma S, Vishwakarma RA, Kaddoumi A, Kumar A, Bharate SB. Synthesis and P-glycoprotein induction activity of colupulone analogs. Org Biomol Chem. 2015 May 21; 13(19):5488-96.
-
Wang D, Ho L, Faith J, Ono K, Janle EM, Lachcik PJ, Cooper BR, Jannasch AH, D'Arcy BR, Williams BA, Ferruzzi MG, Levine S, Zhao W, Dubner L, Pasinetti GM. Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease ß-amyloid oligomerization. Mol Nutr Food Res. 2015 Jun; 59(6):1025-40.
-
Ayyadevara S, Balasubramaniam M, Gao Y, Yu LR, Alla R, Shmookler Reis R. Proteins in aggregates functionally impact multiple neurodegenerative disease models by forming proteasome-blocking complexes. Aging Cell. 2015 Feb; 14(1):35-48.
-
Kim W, Noh H, Lee Y, Jeon J, Shanmugavadivu A, McPhie DL, Kim KS, Cohen BM, Seo H, Sonntag KC. MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons. Mol Neurobiol. 2016 Jan; 53(1):95-108.
-
Bharate JB, Wani A, Sharma S, Reja SI, Kumar M, Vishwakarma RA, Kumar A, Bharate SB. Synthesis, and the antioxidant, neuroprotective and P-glycoprotein induction activity of 4-arylquinoline-2-carboxylates. Org Biomol Chem. 2014 Aug 28; 12(32):6267-77.
-
Altmann A, Tian L, Henderson VW, Greicius MD. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014 Apr; 75(4):563-73.
-
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):322-33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|